University of Nottingham
|Nottingham NG7 2RD|
Prof. C. Hollis
|Dr Kapil Sayal|
Description of the organization
The University of Nottingham is one of the UK's leading research universities and was ranked among the top 7 UK Universities on research power in the most recent Research Assessment Exercise (RAE 2008). The Times Higher World Rankings in 2008 placed Nottingham in the top 1% of all universities worldwide. The University is currently actively collaborating with over 300 research and industrial partners across the whole of Europe. The Division of Psychiatry is in the leading group of research‐led psychiatry departments in the UK. It holds major grants from Research Councils, leading UK charities and governmental sources. It has particular strengths in multi‐disciplinary population studies, social psychiatry and epidemiology and evaluations of innovative health care interventions. The Section of Developmental Psychiatry is a leading child and adolescent mental health research centre in the UK (total grant income over £1 million in the last RAE cycle) and has an international reputation for delivering high quality research. Key research areas include ADHD, early onset psychosis/schizophrenia and Tourette Syndrome using methodologies including developmental epidemiology, cognitive neuroscience/ neuroimaging and translational health services research. The University of Nottingham has close links with the National Health Service (NHS) and has established the Nottingham Institute of Mental Health in partnership with local NHS Trusts to implement evidence based practice and innovative health service research. The Section of Developmental Psychiatry provides leadership of ADHD services for a population of 1 million people in the East Midlands region of England.
The WP7 lead (Professor Chris Hollis) has extensive experience as principal investigator of managing large collaborative ADHD and neurodevelopmental research projects. These projects funded by the Wellcome Trust, PPP Medical Foundation, Medical Research Council and National Institute of Health Research, have both recruited clinical samples and conducted secondary analyses of UK population based databases. Professor Hollis has wide experience in the field of child and adolescent psychopharmacology and was pharmacology lead for the 2008 NICE ADHD Guideline.
Profile of staff members
Prof. Chris Hollis (MRCPsych PhD) is an academic child and adolescent psychiatrist leading a research programme in ADHD worth € 1,5 million. This work has integrated a range of research methodologies including epidemiology, clinical characterization and follow‐up, neuropsychology, neuroimaging (sMRI/fMRI) and electrophysiology (EEG/ERP).
Dr. Kapil Sayal, (MRCPsych, PhD) is an academic child and adolescent psychiatrist whose main research interests include epidemiology and Health Services Research. He is Principal Investigator on a number of clinical trials and was a member of the 2008 NICE ADHD Guideline Development Group.
Main tasks in the project
This partner is responsible for WP7 (adverse psychiatric effects). In addition, the University of Nottingham will participate and contribute to the other Work Packages including the retrospective data acquisition in WP2 and WP3 and WP4.
The fifth ADDUCE Newsletter is now available!
Here, you can read about the finalisation of the project,
the European Medicines Agency and General Assembly meetings
and the dissemination of the results!
The fourth ADDUCE Newsletter is available!
In this newsletter, you can find some information on the final recruitment status of the 2 main studies:
- the prospective open-label methylphenidate pharmacovigilance study
- the long-term cardiascular effects of methylphenidate use
Also, you can read about the future plans of the project!
More than 1500 children, adolescents and adults across all Europe already took part in our study! Thanks to them, we have already gathered lots of information so we can know a lot more about methylphenidate than ever before!
Did you participate in the ADDUCE studies and are you curious about the latest news on the project?
Here you can find some information!
News for children, April 2015
News for adolescents, April 2015
News for parents, April 2015
The third ADDUCE Newsletter is available!
- the prospective open-label methylphenidate pharmacovigilance study: recruitment status and spin-
- the long-term cardiovascular effects of methylphenidate use: study design and participation
and much more in the ADDUCE Newsletter 3, March 2015
WP3: prospective open-label methylphenidate
- WP8: long-term cardiovascular effects of methylphenidate use
and much more in the ADDUCE Newsletter 2, February 2013
16 - 19 OCTOBER 2016:
4rd EUNETHYDIS International Conference on ADHD, Berlin - Germany
from basis neuroscience to optimised clinical care
17 & 18 APRIL 2016:
ADDUCE Consortium meeting, London - UK
28 - 31 MAY 2015:
5th World Congress on ADHD: from Child to Adult Disorder, Glasgow - Scotland
20 & 21 APRIL 2015:
ADDUCE Consortium meeting, Salina - Italy
21 - 24 MAY 2014:
3rd EUNETHYDIS International Conference on ADHD, Istanbul - Turkey
ADHD and related disorders
19 & 20 MAY 2014:
ADDUCE Consortium meeting, Istanbul - Turkey
3 - 6 OCTOBER 2013:
23rd EUNETHYDIS Network Meeting, Prague Czech Republic
A meeting of the European Network of Hyperkinetic Disorders
6 - 9 JUNE 2013:
4th World Congress on ADHD: from Childhood to Adult Disease, Milan - Italy
4 & 5 JUNE 2013:
ADDUCE Consortium meeting, Milan - Italy
6 & 7 JUNE 2012:
ADDUCE Consortium meeting, Cagliari - Italy
23 MAY 2012:
2nd EUNETHYDIS International Conference on ADHD, Barcelona - Spain